Leveraging Immune Checkpoint Blockades-Based Combined Therapy to Overcome Adaptive Immune Resistance
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".
Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 2751
Special Issue Editor
Special Issue Information
Dear Colleagues,
Tumors employ various tactics to adapt to and eventually resist immune attack, collectively called adaptive immune resistance (AIR). Despite the recent success of immune checkpoint blockades (ICBs) that were found to induce systemic regression of tumors and prolong survival, AIR has held the field back from wider success. The success of other immunotherapies has drawn focus away from ICBs, despite their distinct benefits. As ICBs can treat subsets of ‘inflamed’ cancers infiltrated by pre-primed tumor-reactive T cells, several novel approches (such as CAR-T, oncolytic virus, and cancer vaccines) have the potential to newly prime tumor-reactive T cells. Therefore, combining ICBs with novel immunotherapy would lead to enhanced treatment of a larger fraction of human cancers in the near future.
Based on your expertise in cancer immunotherapy, you are invited to contribute a research paper or review in this Special Issue to highlight the remaining challenges for translation medicine to achieve a selective and durable anti-tumor immune response in advanced cancer patients. Studies focusing on ICBs and adaptive immune resistance through both clinical and pre-clinical investigations are welcome.
Dr. Chunchao Zhu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- adaptive immune resistance
- immune checkpoint blockade
- T cells
- dendritic cells
- tumor antigens
- tumor immune microenvironment
- immunotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
